NewLink Genetics (NLNK) Stock Price, News & Analysis

Company Overview

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma. The company also develops NLG207 in combination with paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer; NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a direct enzymatic inhibitor. The company has collaboration and license agreement with Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe & Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.89 to $14.10
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 547,540 shs
• Market Capitalization: $162.00 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NLNK Stock Analysis - Frequently Asked Questions

How were NewLink Genetics' earnings last quarter?

NewLink Genetics Corp (NASDAQ:NLNK) issued its quarterly earnings data on Wednesday, November, 6th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.27). The biotechnology company earned $0.25 million during the quarter. NewLink Genetics had a negative net margin of 4,592.84% and a negative trailing twelve-month return on equity of 41.50%.

What other stocks do shareholders of NewLink Genetics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NewLink Genetics investors own include Bristol Myers Squibb (BMY), Inovio Pharmaceuticals (INO), Arbutus Biopharma (ABUS), OPKO Health (OPK), Gilead Sciences (GILD), CSLM Acquisition (SPWR) and Sarepta Therapeutics (SRPT).

Company Calendar

• Last Earnings: 11/06/2019
• Today: 6/19/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:NLNK
• CIK: 1126234
• Web: www.newlinkgenetics.com
• Phone: 515-296-5555
• Fax: N/A
• Employees: 55
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$42.99 million
• Net Margins: -4,592.84%
• Pretax Margin: N/A
• Return on Equity: -41.50%
• Return on Assets: -33.95%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.98
• Quick Ratio: 7.98

Sales & Book Value

• Annual Sales: $940 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.11 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 37,328,000
• Free Float: N/A
• Market Cap: $162.00 million
• Optionable: Not Optionable
• Beta: 1.17